Evidence map›Paper›PMID 31695326›Full record

ArticleDrug design, development and therapy2019

Design, synthesis, and biological study of 4-[(2-nitroimidazole-1

Weiyan Cheng, Suhua Wang, Zhiheng Yang, Xin Tian, Yongzhou Hu

Abstract read
In one paragraph

Article in Drug design, development and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Weiyan Cheng *Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, People's Republic of China.
Suhua Wang *Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, People's Republic of China.
Zhiheng YangDepartment of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, People's Republic of China.
Xin TianDepartment of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, People's Republic of China.
Yongzhou HuZhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIn order to get novel EGFR inhibitors exerting more potency in tumor hypoxia than in normoxia.

methodsA series of 4-[(2-nitroimidazole-1

resultsThe structure-activity relationship (SAR) studies revealed that compounds bearing both meta-chloride and para-(2-nitroimidazole-1

conclusionThis study provides insights for developing hypoxia-activated kinase inhibitors.

Indexed as

A549 CellsAniline CompoundsAntineoplastic AgentsCell HypoxiaErbB ReceptorsHT29 CellsHumansInhibitory Concentration 50Molecular Docking SimulationNeoplasmsNitroimidazolesProtein Kinase InhibitorsQuinazolinesStructure-Activity RelationshipAniline CompoundsAntineoplastic AgentsEGFR protein, humanErbB ReceptorsNitroimidazolesProtein Kinase InhibitorsQuinazolines2-nitroimidazole4-anilinoquinazolineEGFR inhibitorhypoxiatumor

Identifiers

PMID31695326
PMCPMC6717862

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.